Roswell Park Scientists Present Five Key Cancer Studies at Clinical Meeting

Why It Matters

The findings could reshape treatment guidelines for breast cancer, CAR‑T accessibility, and AI‑assisted oncology, while the Merit Awards underscore Roswell Park’s research leadership. Highlighting trial‑desert gaps emphasizes the need for broader patient enrollment across the United States.

Key Takeaways

• Five Roswell Park fellows earn ASCO 2026 Merit Awards
• GLP‑1 receptor agonists linked to lower HR⁺/HER2⁻ breast cancer risk
• Study finds 40 million US adults live in cancer‑trial deserts
• CAR‑T therapy shows real‑world survival in patients ≥75 with myeloma
• Large language models benchmarked for breast‑cancer decision support

Pulse Analysis

The American Society of Clinical Oncology’s annual meeting remains the premier venue for unveiling breakthrough oncology research, and Roswell Park’s prominent presence signals its growing influence in the field. By presenting five peer‑reviewed studies, the center highlights a strategic focus on translational work that bridges laboratory insights with real‑world patient outcomes. Topics ranging from metabolic interventions with GLP‑1 receptor agonists to the practical challenges of CAR‑T trial accessibility reflect a broader industry shift toward personalized, equitable care.

Among the highlighted abstracts, the GLP‑1 analysis suggests a potential protective effect against hormone‑receptor‑positive breast cancer in overweight, non‑diabetic women, a finding that could inform future endocrine‑therapy guidelines. Parallel investigations reveal that roughly 40 million Americans reside in regions lacking active gastrointestinal cancer trials, underscoring a persistent geographic disparity that may hinder enrollment and delay therapeutic advances. Meanwhile, real‑world data on CAR‑T in patients aged 75 and older demonstrate tolerable toxicity and meaningful survival, expanding the therapeutic window for a demographic traditionally excluded from early‑phase studies.

The inclusion of a benchmarking study for large language models marks a noteworthy convergence of artificial intelligence and clinical decision‑making. By evaluating LLM performance against standardized oncology exams, Roswell Park provides early evidence that AI could augment physician judgment, especially in complex breast‑cancer cases. Coupled with the Merit Awards granted to five emerging investigators, these contributions reinforce the center’s reputation as an incubator of innovative research, while also prompting industry stakeholders to address trial‑desert inequities and integrate AI tools responsibly into oncology practice.